MARKSANS Marksans Pharma Q4 FY25 results (Jan–Mar 2025) and concall
Marksans Pharma reported record revenue and profit for FY25, driven by strong growth in the US market and an expanding OTC product pipeline. While Q4 saw some margin compression due to higher operating costs, the company remains optimistic about future growth, capacity utilization, and strategic M&A, maintaining a debt-free status and recommending a dividend.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 309 | 312 | 299 |
| EBITDA | 63 | 60 | 52 |
| Net profit | 63 | 55 | 38 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
